FDA places Innate cancer trial on partial clinical hold over CMO issue 14-Jan-2020 By Nick Taylor The US FDA puts Innate Pharma trial on partial clinical hold after learning of CMO problems.
AstraZeneca bolsters immuno-oncology pipeline with $242m Innate stake 24-Oct-2018 By Ben Hargreaves AstraZeneca buys a 9.8% stake and takes up option to acquire full rights for monalizumab from Innate Pharma.